Cell and gene therapy (CGT) manufacturers can struggle to move from lab-scale to clinical-scale production. Automation can help but, to make a success of the transition, developers must be willing to learn from other industries.
So says Josh Ludwig, global director of commercial operations at ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf, who believes a lack of scale-up expertise is the issue.
“The biggest challenge CGT manufacturers face is the need to quickly create a viable manufacturing operation that can scale out practically as clinical patient demand increases. As things currently stand, CGT companies are poorly equipped to recognize how to establish scalability or meet the need for speed.
“Establishment of a viable manufacturing operation requires detailed knowledge that is not present in the CGT field. Well-understood principles and methods are found throughout hundreds of industries, but they are foreign to the field of CGT. The most basic aspects of efficient manufacturing are missing,” he tells GEN.
Ludwig points to the automotive and medical device industries as examples of sectors that are well-versed in the steps needed for effective scaleup.
“Over decades, highly competitive regulated industries that have to make thousands of products or more, like cars or medical devices, have developed systems and processes that are highly effective at manufacturing scale out with high quality and exceptional efficiency. Unfortunately, the CGT industry has failed to employ people that have this kind of deep knowledge and experience.”
Clinical data focus
Another issue is the fact many CGT developers are venture capital backed, rather than revenue-generating. This funding structure can mean there is pressure to develop production processes sufficient to support early-phase development rather than late-stage trials and commercialization.
Ludwig says: “All too often, CGT fail to create the systems and processes to make drug products in a practical and scalable manner before time and money run out. Even if a manufacturing process is created and clinical data is obtained, the process is virtually certain to be inadequate at late-stage clinical or commercial scale.”
In addition, some venture-funded CGT companies coming out of academia fail to recognize the benefit of hiring people with deep know-how and experience in efficiently manufacturing products at scale.
“Instead, they hand their manufacturing process off to people with a solid academic pedigree in a biological-related science, maybe a couple of stints at other CGT companies, with a total manufacturing experience of making less than 100 products,” Ludwig adds.
Automation
In Ludwig’s view automation can solve many of the challenges involved in making cell and gene therapies. However, using automated systems correctly also requires expertise.
“The reality is that there are many entities talking about automation, and it will have its place someday. However, until there are true manufacturing people from other industries that are welcomed into the CGT field, it will be misapplied.
“The good news is that CGT drug product manufacturing is a liquid handling problem and that makes it ideal for automation,” he continued, adding “When automation is applied properly to this industry, it will resemble the current processes of producing household goods such as hand soap to commonly used drugs such as insulin.”
https://www.genengnews.com/topics/bioprocessing/automation-and-knowhow-vital-for-cell-and-gene-therapy-scaleup/

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
